

# Psychosocial Aspects of Diabetes Technologies: Commentary on the Current Status of the Evidence and Suggestions for Future Directions

Journal of Diabetes Science and Technology  
1–7

© 2024 Diabetes Technology Society

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/19322968241276550

journals.sagepub.com/home/dst



Katharine Barnard-Kelly, PhD<sup>1</sup>, Linda Gonder-Frederick, PhD<sup>2</sup>,  
Jill Weissberg-Benchell, PhD<sup>3,4</sup>, and Lauren E. Wisk, PhD<sup>5,6</sup>

## Abstract

Diabetes technologies, including continuous glucose monitors, insulin pumps, and automated insulin delivery systems offer the possibility of improving glycemic outcomes, including reduced hemoglobin A1c, increased time in range, and reduced hypoglycemia. Given the rapid expansion in the use of diabetes technology over the past few years, and touted promise of these devices for improving both clinical and psychosocial outcomes, it is critically important to understand issues in technology adoption, equity in access, maintaining long-term usage, opportunities for expanded device benefit, and limitations of the existing evidence base. We provide a brief overview of the status of the literature—with a focus on psychosocial outcomes—and provide recommendations for future work and considerations in clinical applications. Despite the wealth of the existing literature exploring psychosocial outcomes, there is substantial room to expand our current knowledge base to more comprehensively address reasons for differential effects, with increased attention to issues of health equity and data harmonization around patient-reported outcomes.

## Keywords

automated insulin delivery, continuous glucose monitors, psychosocial aspects, type 1 diabetes

## Background

Diabetes technologies, including continuous glucose monitors (CGMs), insulin pumps, and automated insulin delivery (AID) systems, offer the possibility of improving glycemic outcomes, including reduced A1c, increased time in range, and reduced hypoglycemia.<sup>1–3</sup> Technology use has increased worldwide, with rates of CGM use in both youth and adults rising. In a US study assessing national trends in CGM use among individuals with commercial insurance, the rate of CGM use rose from 20% between 2010 and 2013 to 49.78% in 2016 to 2019, a 2.5-fold increase in less than ten years' time.<sup>4</sup> In the United Kingdom, the rate of CGM use has increased to eight in ten adults with type 1 diabetes (T1D) in the span of a few years.<sup>5–7</sup> Insulin pump use has seen an increase in uptake as well, with 63% of individuals using pumps in 2019 in the United States, up from 57% in 2012.<sup>5</sup> Prevalence among minoritized groups, however, remains significantly lower with non-Hispanic white individuals almost twice as likely as black and Hispanic individuals to access such technologies.<sup>8</sup> Given the rapid expansion in use, and touted promise of these devices for improving both

clinical and psychosocial outcomes, it is critically important to understand issues in technology adoption, equity in access, maintaining long-term usage, opportunities for expanded device benefit, and limitations of the existing evidence base. The purpose of this article is to provide a brief overview of

<sup>1</sup>Southern Health NHS Foundation Trust, Southampton, UK

<sup>2</sup>Department of Psychiatry and Neurobehavioral Sciences, School of Medicine, University of Virginia, Charlottesville, VA, USA

<sup>3</sup>Pritzker Department of Psychiatry and Behavioral Health, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA

<sup>4</sup>Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

<sup>5</sup>Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA

<sup>6</sup>Department of Health Policy and Management, UCLA Fielding School of Public Health, Los Angeles, California, USA

## Corresponding Author:

Jill Weissberg-Benchell, PhD, Pritzker Department of Psychiatry and Behavioral Health, Ann and Robert H. Lurie Children's Hospital of Chicago, 225 East Chicago Avenue, Box 10, Chicago, IL 60611, USA.  
Email: jwbenchell@luriechildrens.org

the evidence, clinical application, and future directions of diabetes technologies. We have focused specifically on psychosocial outcomes and provide recommendations for future work and considerations in clinical applications.

## How are Benefits of Technologies Defined?

Early efficacy studies of these technologies focused nearly exclusively on the improvements in glycemic control, as measured by changes in hemoglobin A1c; while subsequent work has turned our attention toward the potential of these devices for reducing the emotional burden of the daily management of diabetes, the user experience, and related changes to key psychosocial constructs. Despite compelling evidence of the glycemic benefits of these technologies, research on the psychosocial impact has been mixed. Conceptually, such mixed findings may be expected, as diabetes technology can alleviate task-specific burdens and related distress (such as frequent daily blood glucose monitoring in the case of CGMs and multiple daily injections in the case of insulin pumps) and provide important opportunities for real-time, fine-tuned adjustments in dosing (such as time-varying and fractional insulin ratios with an insulin pump and automated correction doses with AID systems). These systems may also exacerbate diabetes distress due to common alerts and alarms (implemented for safety reasons and often outside of user control regarding frequency, timing, and noise level), the necessity of wearing large, electronic devices that are physically affixed to a body nearly around the clock, and the startup and continuation cost of acquiring these devices (eg, the need for specialty pharmacies to fill orders, and the time required to complete insurance paperwork and prior authorizations for durable medical equipment in United States contexts). Collectively, these burdens can affect not only daily diabetes distress, but also sleep quality, self-confidence and perception, ability to effectively utilize the devices, financial burden, and several other inter-personal and intra-personal concerns.

Indeed, these negative aspects of device use are reflected in empirical work<sup>9</sup> that attributes them to device discontinuation and barriers to initiation. Of those discontinuing CGM use in a large registry study, 32% were bothered by alarms, a further 20% to 30% perceived the device to be inaccurate or reported a general mistrust of the device, and 29% felt that the CGM took too much time and effort to use. Even among current CGM users, 47% reported the hassle of wearing the device was a barrier for continued use. Divan et al<sup>10</sup> found that participants expressed concerns related to the cost of the devices, the physical discomfort related to using the device, and a sense of not trusting the data. Similar findings related to perceived barriers have been reported in studies assessing the perceptions of parents of young children<sup>11</sup> and of teenagers.<sup>12</sup> Perceived benefits of technologies have also been assessed in these studies, with participants reporting

technology use makes caring for diabetes easier,<sup>10</sup> decreases parents' worry, increases their sense of safety, and improves their sleep,<sup>11</sup> and that teens appreciate being able to have access to their data including trend arrows to inform their next steps.<sup>13</sup>

In recent years, more research in diabetes technology has assessed person-reported outcome data and measures of psychosocial impacts. Although findings across studies have been mixed, positive results have been shown in several studies. For instance, CGM and AID use has been attributed to improvements in diabetes-specific emotional distress,<sup>14-24</sup> reductions in fear of hypoglycemia,<sup>17,19,24-27</sup> improvements in sleep quality,<sup>17,19,28-31</sup> improvement in quality of life,<sup>24,30,32-34</sup> and increased treatment satisfaction.<sup>14,23,28,30-33,35,36</sup> There is a conflicting evidence base that has shown null findings across many of these outcomes<sup>14,17,18,20,23-25,27,31,32,34-41</sup>; importantly, there is no evidence that technology use contributes to a worsening of psychosocial status for the majority of people. A minority of studies have sought to explain differences in the impact of technology use on psychosocial outcomes by examining potential effect modifiers,<sup>21</sup> but this remains a substantially under-investigated area of research.

Assessing the psychosocial impact of diabetes technology is necessary as the success of these technologies is predicated upon whether the user finds more benefits than burdens<sup>20,27</sup> and is therefore willing to not only try the device, but also continue using it. For example, while there is a wealth of evidence demonstrating that CGM devices can be associated with increased self-efficacy in diabetes self-management through immediate feedback of blood glucose levels and trends, this is not the case for all. Unfortunately, they also have the potential to increase learned helplessness as people with diabetes report that whatever they do in terms of self-management is never enough<sup>42</sup>; and national diabetes audit data show stubbornly sub-optimal glycemic result data year on year, despite the growing use of diabetes technologies.<sup>43</sup>

Device manufacturers are consistently iterating on the design and features of these devices and may be able to address some of the concerns identified as barriers to use but it is unlikely that all potential concerns will be addressed on a short time scale. In the interim, it will be critical for providers to collaborate with each individual patient, work to match the demand characteristics of each system with that person's needs and expectations, and clearly discuss both the potential benefits and the potential downsides when using each system, particularly during onboarding, to mentally and emotionally prepare patients for the realities of device use. In order for people with diabetes and their loved ones to achieve satisfaction and the desired positive results from the use of diabetes technologies, they must perceive the benefits outweigh the burdens. This is particularly relevant since each system currently on the market varies with respect to both the system features and functionality, and the level of interaction with the system needed by the user. Currently, the

systems differ<sup>44</sup> with respect to the hardware (the pump and the CGM system that is used), the alarm burden, the degree of user input required for system functioning, the ability of the user to adjust the algorithm, and the ability of the system to compensate for changes in work/life demands (such as shift work).<sup>45</sup> A personalized experience with each system will be predicated on the match between an individual's preferences, needs and expectations of a system,<sup>46,47</sup> and each system's specific features and functionality.

This discrepancy between individuals' expectations for reduced behavioral demand and the reality of the need for continued engagement in self-management behaviors has emerged in recent studies of AID devices. A clinical trial in adults 60 years of age and older found reduced fear of hypoglycemia as well as decreased psychological burden and improved sleep with use of this technology.<sup>48</sup> However, although participants reported reduced daily effort with AID in structured interviews, they also expressed disappointment that the system did not act more like a healthy pancreas and required more effort on their part than they had expected. These reports were consistent with the questionnaires completed by these older adults before and after the trial, which showed positive expectations for AID before use and, after use, continued positive reactions but a decrease in the degree of positivity. As noted above, setting realistic expectations for users is a critical part of education for onboarding to AID devices. This includes information about the continued need for meal and correction boluses for some of the current systems, as well as strategies for avoiding over-treatment of hypoglycemia and hyperglycemia.<sup>3</sup> A recent real-world data set of over 19 000 AID users examined glycemic outcomes during the first three months of use of the system.<sup>49</sup> For those individuals whose average number of daily self-administered meal and correction boluses stayed consistent with pre-AID use, average time in range achieved was 84%. In contrast, those who showed a decrease in daily self-initiated meal and correction boluses achieved a much lower average time in range of 54%. These findings demonstrate that, at least with some hybrid closed-loop systems, achieving optimal glycemic outcomes remains dependent on the behavioral effort of the user.

### **Onboarding: Timing and Content**

Unfortunately, very little research has examined the process of onboarding to new technologies and how this experience contributes to continuation or discontinuation of technology usage. There is no evidence base for the development of programs to educate and support individuals during the early stages of use. The available evidence for AID systems suggests that early device use, specifically time spent in Auto Mode, is a predictor of longer-term success with these technologies.<sup>50</sup> Another study of discontinuation of an open-source AID system found that difficulties learning to use the device effectively were predictive of discontinuation.<sup>51</sup> A

subsequent study found that, six months after initiating use of these systems, reported difficulty during onboarding was associated with poorer psychosocial outcomes, including more diabetes distress in adults, increased fear of hypoglycemia in children, and poorer sleep quality in both children and parents.<sup>52</sup> These findings suggest that, after initial onboarding, individuals should be monitored for difficulties in the early stages of adaptation and receive increased education and/or support when problems are experienced. More extensive research is needed to assess the different types of support individuals need during the early phases of technology use, and this information must come from the users themselves and their families/caretakers.

### **Marginalized Groups and Inequality**

As mentioned, we may conceptually expect mixed results regarding the psychosocial impact of diabetes technology, but there are several important limitations and potential biases in this research that also need to be considered when contextualizing the findings. Many of the studies are subject to considerable selection biases whereby well-resourced groups and those with already low to moderate levels of diabetes distress are disproportionately represented. Specifically, of the eight definitive hybrid closed-loop clinical trials in the United States, only 6% and 2.2% of the enrolled individuals were Hispanic and non-Hispanic black, respectively<sup>53</sup>; considerably less than the racial-ethnic prevalence of T1D.<sup>54</sup> This reflects broader disparities in access and uptake of diabetes technologies. Taking continuous glucose monitoring systems, for example, a retrospective chart review of 1509 T1D children found that a significantly higher percentage of white (54%) patients were started on CGM compared with black (31%) and Hispanic (33%) patients ( $P < .001$ ).<sup>8</sup> In a retrospective review of 227 adult T1D patients who were seen in an urban, safety-net endocrinology clinic, investigators found that only 85 patients (37%) used any diabetes technology.<sup>55</sup> Within this cohort, a significantly higher percentage of white patients (55%) used CGM and/or insulin pumps compared with black (28%), Hispanic (28%), or other ethnicities (24%). A significantly lower percentage of black (4%) and Hispanic (9%) patients used both technologies compared with white (35%).

Barriers to technologies among marginalized and economically disadvantaged groups include mistrust of health systems, lack of support, financial constraints, provider biases, stigmatization, stringent insurance policies, and clinical infrastructure.<sup>56</sup> Such inequalities can be overcome by improving awareness, refining and adhering to equity-focused policies, and emphasizing personalized patient-centered approaches to health care delivery. In addition, making access to health care more equitable requires acknowledgment and understanding of social determinants of health (SDOH) and their mutability. For example, while some SDOH are immutable, others, such as inequity in

power, money, and resource (eg, affordability of drugs), can be addressed with targeted health policies. Ultimately, the exclusion of historically marginalized groups who are the least likely to have access to diabetes technology<sup>57,58</sup> reveals a blind spot in our understanding of the distribution of psychosocial burdens of diabetes technology and effective strategies to mitigate them while simultaneously addressing equity concerns.<sup>59-61</sup>

## Measurement Issues

There are considerable differences in the psychosocial constructs that are measured across studies, both in terms of underlying constructs addressed (eg, depression versus diabetes distress) and general versus disease-specific measures. While variability in assessed outcomes is important to capture the potential range of effects, in many cases, psychosocial measures are included as secondary (or tertiary) outcomes without consideration of potential causal mechanisms that may link use of diabetes technology to specific psychosocial consequences. In addition, clinical trials are typically not statistically powered to detect significant changes in patient-reported outcomes, which likely contribute to the inconsistent and mixed findings on psychosocial impact. Finally, very few studies specifically look at mechanisms linking outcomes to specific components of diabetes technology, ranging from the device level (pump vs CGM) to the feature level (device size vs alarm configuration). These types of mechanistic inquiries are critically important to direct interventions designed to alleviate device burden and ultimately help patients maximize the potential benefit of their devices.

In addition, clinical trials assessing psychosocial outcomes with self-report measures typically analyze these data at the group level, comparing the control and experimental conditions at critical time points. Such an approach can obscure important information. An example of this is a recent large clinical trial of an AID system that found significant group effects in psychosocial variables, including decreases in diabetes distress, quality of life, stress, anxiety, and fear of hypoglycemia.<sup>62</sup> However, in spite of these group improvements, at the end of the study, 50% of the adults in the AID group still reported clinically severe levels of diabetes distress. These findings point out, not only the value of examining psychosocial outcomes beyond the level of statistically significant group differences, but also the important fact that use of technology will not necessarily eliminate the emotional distress and burden associated with living with diabetes. More research is needed that focuses on individuals who are struggling emotionally and behaviorally to cope with the negative impact of diabetes on their lives, such as those with severe levels of diabetes distress or glycemic instability, and how to leverage diabetes technologies to improve their quality of life and medical outcomes.

Another method that can obtain information and insight beyond group comparisons is the structured interview to gather qualitative data from individuals using diabetes technology.<sup>48,52</sup> An early study using this methodology interviewed individuals both before using AID and after using the system for three months.<sup>63</sup> Despite positive expectations for AID use, participants reported that it took several weeks to develop full trust and confidence in the device. Positive psychosocial benefits included a decrease in emotional, mental and behavioral burden, and improvements in relationships, especially between parents and children, due to decreased parental monitoring and reminders related to diabetes-related tasks. Parents of younger children reported an increased feeling of safety and decrease in the need to be overly vigilant, which in turn allowed them to give their child more freedom to be away from them for age-normal activities, such as playdates and sleepovers. This type of insight into the effects of diabetes technology on family dynamics is difficult, if not impossible, to capture using standardized questionnaires.

## Clinical Considerations and Conclusions

The numerous remaining questions about psychosocial impact notwithstanding, these devices can be life-changing for many living with diabetes, and so it is imperative that practitioners prioritize understanding, communicating, and addressing the sometimes-conflicting forces that can promote or dissuade diabetes technology use among their patients. While there are no formal tools available to assist providers with assessing patient and family perceptions around benefits and burdens of technology, we strongly encourage an open conversation about the range of experiences with these devices that includes a nuanced discussion of possible misperceptions and sets realistic expectations for physiological and psychological outcomes. With sufficient support from the diabetes care team, individuals may be more likely to initiate and persist in their use of these technologies, and thus reap demonstrated benefits in glycemic outcomes. Additional research that fully explores effect heterogeneity in the ways in which diabetes technology can impact psychosocial outcomes will be critical for personalizing strategies to optimize technology use among individuals. Utilizing a core set of patient-reported psychosocial outcomes, harmonized across future studies, as well as seeking to recruit maximally diverse samples of participants (with regards to both sociodemographic and clinical characteristics), should be critical goals for future research to optimize investigator's ability to evaluate important effect heterogeneity.

Substantial evidence supports the promise of diabetes technology for improving both glycemic and psychosocial outcomes. Despite the wealth of the existing literature exploring the latter effects, there is substantial room to expand our current knowledge base to more comprehensively address

reasons for differential effects. This information will prove critically important for establishing best practices for practitioners in supporting patients who choose to use these devices.

### Abbreviations

AID, automated insulin delivery; CGM, continuous glucose monitors; T1D, type 1 diabetes.

### Acknowledgments

The authors wish to acknowledge Kate Diaz Roldan, MPH, for her assistance in preparing this manuscript. Authors are listed in alphabetical order.

### Declaration of Conflicting Interests


The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.


### Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### ORCID iDs

Katharine Barnard-Kelly  <https://orcid.org/0000-0002-3888-3123>

Jill Weissberg-Benchell  <https://orcid.org/0000-0002-4396-6337>

Lauren E. Wisk  <https://orcid.org/0000-0003-2932-4140>

### References

1. Bekiari E, Kitsios K, Thabit H, et al. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. *BMJ*. 2018;361:k1310.
2. Boughton CK, Hovorka R. Automated insulin delivery in adults. *Endocrinol Metab Clin North Am*. 2020;49(1):167-178.
3. Sherr JL, Heinemann L, Fleming GA, et al. Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the joint diabetes technology working group of the European Association for the study of diabetes and the American Diabetes Association. *Diabetes Care*. 2022;45(12):3058-3074.
4. Lacy ME, Lee KE, Atac O, et al. Patterns and trends in continuous glucose monitoring utilization among commercially insured individuals with type 1 diabetes: 2010-2013 to 2016-2019. *Clin Diabetes*. 2024;42(3):388-397.
5. Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. *Diabetes Technol Ther*. 2019;21(2):66-72.
6. NHS England. Rapid NHS rollout sees 200,000 diabetes patients get lifechanging devices [Press Release]. Published 2022. Accessed July 16, 2024. <https://www.england.nhs.uk/2022/12/rapid-nhs-rollout-sees-200000-diabetes-patients-get-lifechanging-devices/>
7. Miller KM, Hermann J, Foster N, et al. Longitudinal changes in continuous glucose monitoring use among individuals with type 1 diabetes: international comparison in the German and Austrian DPV and US T1D exchange registries. *Diabetes Care*. 2020;43(1):e1-e2.
8. Lai CW, Lipman TH, Willi SM, Hawkes CP. Racial and ethnic disparities in rates of continuous glucose monitor initiation and continued use in children with type 1 diabetes. *Diabetes Care*. 2021;44(1):255-257.
9. Lanning MS, Tanenbaum ML, Wong JJ, Hood KK. Barriers to continuous glucose monitoring in people with type 1 diabetes: clinician perspectives. *Diabetes Spectr*. 2020;33(4):324-330.
10. Divan V, Greenfield M, Morley CP, Weinstock RS. Perceived burdens and benefits associated with continuous glucose monitor use in type 1 diabetes across the lifespan. *J Diabetes Sci Technol*. 2022;16(1):88-96.
11. Hilliard ME, Levy W, Anderson BJ, et al. Benefits and barriers of continuous glucose monitoring in young children with type 1 diabetes. *Diabetes Technol Ther*. 2019;21(9):493-498.
12. Messer LH, Tanenbaum ML, Cook PF, et al. Cost, hassle, and on-body experience: barriers to diabetes device use in adolescents and potential intervention targets. *Diabetes Technol Ther*. 2020;22(10):760-767.
13. Lawton J, Blackburn M, Allen J, et al. Patients' and caregivers' experiences of using continuous glucose monitoring to support diabetes self-management: qualitative study. *BMC Endocr Disord*. 2018;18(1):12.
14. Adams RN, Tanenbaum ML, Hanes SJ, et al. Psychosocial and human factors during a trial of a hybrid closed loop system for type 1 diabetes management. *Diabetes Technol Ther*. 2018;20(10):648-653.
15. Al Hayek AA, Robert AA, Al Dawish MA. Effectiveness of the freestyle libre flash glucose monitoring system on diabetes distress among individuals with type 1 diabetes: a prospective study. *Diabetes Ther*. 2020;11(4):927-937.
16. Al Hayek AA, Robert AA, Al Dawish MA. Acceptability of the freestyle libre flash glucose monitoring system: the experience of young patients with type 1 diabetes. *Clin Med Insights Endocrinol Diabetes*. 2020;13:1-7.
17. Bisio A, Brown SA, McFadden R, et al. Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents. *Pediatr Diabetes*. 2021;22(3):495-502.
18. Bisio A, Gonder-Frederick L, McFadden R, et al. The impact of a recently approved automated insulin delivery system on glycemic, sleep, and psychosocial outcomes in older adults with type 1 diabetes: a pilot study. *J Diabetes Sci Technol*. 2022;16(3):663-669.
19. Burckhardt MA, Roberts A, Smith GJ, Abraham MB, Davis EA, Jones TW. The use of continuous glucose monitoring with remote monitoring improves psychosocial measures in parents of children with type 1 diabetes: a randomized crossover trial. *Diabetes Care*. 2018;41(12):2641-2643.
20. Kudva YC, Laffel LM, Brown SA, et al. Patient-reported outcomes in a randomized trial of closed-loop control: the pivotal international diabetes closed-loop trial. *Diabetes Technol Ther*. 2021;23(10):673-683.
21. Polonsky WH, Fortmann AL. Impact of real-time continuous glucose monitoring data sharing on quality of life and health outcomes in adults with type 1 diabetes. *Diabetes Technol Ther*. 2021;23(3):195-202.
22. Vesco AT, Jedraszko AM, Garza KP, Weissberg-Benchell J. Continuous glucose monitoring associated with less diabetes-specific emotional distress and lower A1c among adolescents

- with type 1 diabetes. *J Diabetes Sci Technol*. 2018;12(4):792-799.
23. Weissberg-Benchell J, Hessler D, Fisher L, Russell SJ, Polonsky WH. Impact of an automated bihormonal delivery system on psychosocial outcomes in adults with type 1 diabetes. *Diabetes Technol Ther*. 2017;19(12):723-729.
  24. Weissberg-Benchell J, Vesco AT, Shapiro J, et al. Psychosocial impact of the insulin-only iLet bionic pancreas for adults, youth, and caregivers of youth with type 1 diabetes. *Diabetes Technol Ther*. 2023;25(10):705-717.
  25. Cobry EC, Bisio A, Wadwa RP, Breton MD. Improvements in parental sleep, fear of hypoglycemia, and diabetes distress with use of an advanced hybrid closed-loop system. *Diabetes Care*. 2022;45(5):1292-1295.
  26. Ng SM, Moore HS, Clemente MF, Pintus D, Soni A. Continuous glucose monitoring in children with type 1 diabetes improves well-being, alleviates worry and fear of hypoglycemia. *Diabetes Technol Ther*. 2019;21(3):133-137.
  27. Weissberg-Benchell J, Hessler D, Polonsky WH, Fisher L. Psychosocial impact of the bionic pancreas during summer camp. *J Diabetes Sci Technol*. 2016;10(4):840-844.
  28. Burckhardt MA, Abraham MB, Mountain J, et al. Improvement in psychosocial outcomes in children with type 1 diabetes and their parents following subsidy for continuous glucose monitoring. *Diabetes Technol Ther*. 2019;21(10):575-580.
  29. Burckhardt MA, Fried L, Bebbington K, et al. Use of remote monitoring with continuous glucose monitoring in young children with Type 1 diabetes: the parents' perspective. *Diabet Med*. 2019;36(11):1453-1459.
  30. Pinsker JE, Müller L, Constantin A, et al. Real-world patient-reported outcomes and glycemic results with initiation of Control-IQ technology. *Diabetes Technol Ther*. 2021;23(2):120-127.
  31. Wheeler BJ, Collins OJ, Meier RA, et al. Improved technology satisfaction and sleep quality with Medtronic MiniMed® advanced hybrid closed-loop delivery compared to predictive low glucose suspend in people with type 1 diabetes in a randomized crossover trial. *Acta Diabetol*. 2022;59(1):31-37.
  32. Abraham MB, de Bock M, Smith GJ, et al. Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes: a randomized clinical trial. *JAMA Pediatr*. 2021;175(12):1227-1235.
  33. Al Hayek AA, Al Dawish MA. The potential impact of the freestyle libre flash glucose monitoring system on mental well-being and treatment satisfaction in patients with type 1 diabetes: a prospective study. *Diabetes Ther*. 2019;10(4):1239-1248.
  34. McAuley SA, Lee MH, Paldus B, et al. Six months of hybrid closed-loop versus manual insulin delivery with fingerprick blood glucose monitoring in adults with type 1 diabetes: a randomized, controlled trial. *Diabetes Care*. 2020;43(12):3024-3033.
  35. Berget C, Messer LH, Vigers T, et al. Six months of hybrid closed loop in the real-world: an evaluation of children and young adults using the 670G system. *Pediatr Diabetes*. 2020;21(2):310-318.
  36. Laffel LM, Kanapka LG, Beck RW, et al. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. *JAMA*. 2020;323(23):2388-2396.
  37. Barnard KD, Wysocki T, Ullly V, et al. Closing the loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: a psychosocial substudy. *J Diabetes Sci Technol*. 2017;11(6):1080-1088.
  38. Cobry EC, Hamburger E, Jaser SS. Impact of the hybrid closed-loop system on sleep and quality of life in youth with type 1 diabetes and their parents. *Diabetes Technol Ther*. 2020;22(11):794-800.
  39. Cobry EC, Kanapka LG, Cengiz E, et al. Health-related quality of life and treatment satisfaction in parents and children with type 1 diabetes using closed-loop control. *Diabetes Technol Ther*. 2021;23(6):401-409.
  40. Polonsky WH, Hessler D, Ruedy KJ, Beck RW; DIAMOND Study Group. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes: further findings from the DIAMOND randomized clinical trial. *Diabetes Care*. 2017;40(6):736-741.
  41. Sinisterra M, Hamburger S, Tully C, Hamburger E, Jaser S, Streisand R. Young children with type 1 diabetes: sleep, health-related quality of life, and continuous glucose monitor use. *Diabetes Technol Ther*. 2020;22(8):639-642.
  42. Abdoli S, Miller-Bains K, Fanti P, Silveira MSVM, Hessler D. Development and validation of a scale to measure diabetes burnout. *J Clin Transl Endocrinol*. 2021;23:100251.
  43. NHS England. National diabetes audit dashboards [Internet]. Accessed October 17, 2023. <https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/national-diabetes-audit/dashboards>
  44. Phillip M, Nimri R, Bergenstal RM, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. *Endocr Rev*. 2023;44(2):254-280.
  45. O'Malley G, Messer LH, Levy CJ, et al. Clinical management and pump parameter adjustment of the Control-IQ closed-loop control system: results from a 6-month, multicenter, randomized clinical trial. *Diabetes Technol Ther*. 2021;23(4):245-252.
  46. Garza KP, Howard KR, Weissberg-Benchell J, Feldman M; Bionic Pancreas Group. 52-LB: adult's lived experience using the insulin-only bionic pancreas. *Diabetes*. 2022;71(suppl 1):52.
  47. Howard KR, Garza KP, Feldman M, Weissberg-Benchell J. Parent, child, and adolescent lived experience using the insulin-only iLet Bionic Pancreas. *J Pediatr Psychol*. 2024;49(6):413-420.
  48. Kubilay E, Trawley S, Ward GM, et al. Lived experience of older adults with type 1 diabetes using closed-loop automated insulin delivery in a randomised trial. *Diabet Med*. 2023;40(4):e15020.
  49. Kovatchev BP, Singh H, Mueller L, Gonder-Frederick LA. Biobehavioral changes following transition to automated insulin delivery: a large real-life database analysis. *Diabetes Care*. 2022;45(11):2636-2643.
  50. Forlenza GP, Vigers T, Berget C, et al. Predicting success with a first-generation hybrid closed-loop artificial pancreas system among children, adolescents, and young adults with type 1 diabetes: a model development and validation study. *Diabetes Technol Ther*. 2022;24(3):157-166.
  51. Wong JJ, Suttiratana SC, Lal RA, et al. Discontinued use of the loop insulin dosing system: a mixed-methods investigation. *Diabetes Technol Ther*. 2022;24(4):241-248.

52. Wong JJ, Hood KK, Hanes SJ, Lal RA, Naranjo D. Psychosocial effects of the loop open-source automated insulin delivery system. *J Diabetes Sci Technol*. 2023;17(6):1440-1447.
53. Akturk HK, Agarwal S, Hoffecker L, Shah VN. Inequity in racial-ethnic representation in randomized controlled trials of diabetes technologies in type 1 diabetes: critical need for new standards. *Diabetes Care*. 2021;44(6):e121-e123.
54. Dabelea D, Mayer-Davis EJ, Saydah S, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. *JAMA*. 2014;311(17):1778-1786.
55. Fantasia KL, Wirunsawanya K, Lee C, Rizo I. Racial disparities in diabetes technology use and outcomes in type 1 diabetes in a safety-net hospital. *J Diabetes Sci Technol*. 2021;15(5):1010-1017.
56. Kanbour S, Everett E. Addressing disparities in technology use among patients with type 1 diabetes: a review. *Curr Opin Endocrinol Diabetes Obes*. 2024;31(1):14-21.
57. Everett EM, Wisk LE. Relationships between socioeconomic status, insurance coverage for diabetes technology and adverse health in patients with type 1 diabetes. *J Diabetes Sci Technol*. 2022;16(4):825-833.
58. Everett EM, Wright D, Williams A, et al. A longitudinal view of disparities in insulin pump use among youth with type 1 diabetes: the SEARCH for diabetes in youth study. *Diabetes Technol Ther*. 2023;25(2):131-139.
59. Agarwal S, Schechter C, Gonzalez J, Long JA. Racial-ethnic disparities in diabetes technology use among young adults with type 1 diabetes. *Diabetes Technol Ther*. 2021;23(4):306-313.
60. Ju Z, Piarulli A, Bielick L, Marschall S, Brouillard E, Steenkamp D. Advanced diabetes technology remains underutilized in underserved populations: early hybrid closed-loop system experience at an academic safety net hospital. *Diabetes Technol Ther*. 2022;24(2):143-147.
61. Kanbour S, Jones M, Abusamaan MS, et al. Racial disparities in access and use of diabetes technology among adult patients with type 1 diabetes in a US academic medical center. *Diabetes Care*. 2023;46(1):56-64.
62. Reznik Y, Bonnemaïson E, Fagherazzi G, et al. The use of an automated insulin delivery system is associated with a reduction in diabetes distress and improvement in quality of life in people with type 1 diabetes. *Diabetes Obes Metab*. 2024;26(5):1962-1966.
63. Lawton J, Blackburn M, Rankin D, et al. Participants' experiences of, and views about, daytime use of a day-and-night hybrid closed-loop system in real life settings: longitudinal qualitative study. *Diabetes Technol Ther*. 2019;21(3):119-127.